PPARA and metabolic dysfunction-associated steatohepatitis: It is characterized by reduced levels of metabolic or energy homeostatic processes, including PPAR signaling—a pathway regulating lipid metabolism and inflammation, and an anti‐NASH drug target under active development (Gross et al, 2017; Boeckmans et al, 2019; Wu et al, 2020).